SRAD enters September with a sharp divergence between analyst conviction and market positioning — a $22 Wolfe Research target arriving just as the stock trades at $12.31, down 15% over the past month and 4.6% on the week.
The most notable development this week is Wednesday's initiation from Wolfe Research, where analyst Peter Supino launched coverage with an Outperform rating and a $22 price target — 79% above Tuesday's close. That stands in contrast to the mood after the August 3 earnings print, which triggered a wave of target cuts across the Street. UBS downgraded to Neutral and halved its target from $30 to $16. JPMorgan, Citigroup, Macquarie, and several others maintained buy-equivalent ratings but all trimmed targets, clustering in the $15–$26 range. The consensus remains buy-leaning — 14 analysts with positive ratings, mean target at $16.15 — but the post-earnings reset makes Wolfe's fresh $22 entry look like the most constructive read on the tape right now.
The Street debate is well-defined. Bulls point to Sportradar's B2B infrastructure positioning in sports betting, its subscription-revenue base, positive 2026 guidance on EBITDA and free cash flow conversion, and a new agreement with Kalshi opening prediction-market exposure. Bears flag the company's gray-market exposure, limited margin expansion runway, a valuation premium versus peer Genius Sports, and the conspicuous absence of an NBA data deal from recent partnership announcements. The EV/EBITDA multiple has drifted higher over 30 days to 7.1x despite the price decline, reflecting earnings-estimate cuts running faster than the stock itself. The short score of 70.2 puts SRAD in the bottom decile on that dimension — a meaningful signal worth carrying into the positioning read.
The borrow market tells a more urgent story than the headline short interest level. Availability has tightened dramatically — from a loose 194% in late July to just 22% now, close to the 52-week floor of 19%. In practical terms, for every share currently borrowed, only about one in five remains available to lend. That tightening happened fast: availability was above 100% as recently as August 11. Short interest in share terms is roughly 15.5 million, up about 15% over the past month even as it edged down fractionally this week. Borrowing costs remain low at 0.94% — not a squeeze-risk signal on their own — but the rapid drain on available supply warrants attention. The short score ranking and utilization rank both sit in the bottom decile of the ORTEX universe, underscoring that the lending market has become notably tighter in a short time.
Options positioning has also shifted. The put/call ratio has risen to 0.31, above its 20-day average of 0.28 and running about 1.2 standard deviations higher than recent norms — a mild but real uptick in defensive hedging. That is still far from the 52-week high of 0.75, so this is caution rather than panic. The move coincides with the stock's worst monthly stretch in some time. Peer DKNG fell 9.1% on the week, and FLUT dropped 5% — sector-wide pressure that gives some cover to SRAD's slide, even if the earnings-driven target cuts are company-specific.
One institutional footnote worth flagging: Spruce House Investment Management filed a fresh Schedule 13G in August, disclosing a 5.8% stake of roughly 12.5 million shares — a new position. T. Rowe Price filed an amendment showing its stake fell from 5.5% to 4.6%, dropping it below the 5% disclosure threshold. As always with 13D/G filings, stakes are as-last-disclosed, and holders who drift below 5% may not file again. The Spruce House entry is the more interesting signal — a new institutional buyer at current levels, against a backdrop where other holders were trimming after the earnings reset.
The next scheduled earnings date is November 4. Between now and then, the key variables to watch are whether the borrow availability floor holds near its recent lows, whether Wolfe's bullish initiation draws follow-on analyst upgrades, and whether any NBA data-rights news resolves what the bear case identifies as a notable gap in Sportradar's partnership story.
See the live data behind this article on ORTEX.
Open SRAD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
